Genesis, Evaluation and Progression of A Breakthrough
Discovery to Efficiently Cure Cancer Through Use of Dr.
M.S. Reddy’s Multiple Mixed Strain Probiotics as Adjuvants
Along with the Traditional Cancer Therapies, Through
Restoration of Healthy and Balanced Intestinal Microbiota
and their Microbiome
A breakthrough, Multiple Mixed Strain Probiotic Therapy, although originally designed to cure hospital acquired infections, has
been discovered serendipitously by Dr. M.S. Reddy to treat cancer with greatest accuracy (60% as opposed to current 20%), with
least or no side effects and least or no relapse, when used as an adjuvant therapy along with standard cancer therapies, including
immune checkpoint therapy. This discovery can be further refined and improved to treat cancer at 80 to 100% efficacy to save
lives of millions of people in the world by significantly improving immune system through positive manipulation of the human
gut microbiota and their microbiome. The results of the clinical trials are outlined along with discussion and conclusion. The
references listed have been limited to the latest, significant, and directly applicable research discoveries only.
Keywords: Dr MS Reddy’s multiple mixed strain probiotic therapy to treat hospital acquired infections; Nosocomial infections; Dr
MS Reddy multiple mixed strain adjuvant cancer therapy; Microbiota; Hospital acquired infections; Immune checkpoint therapy; C
Diff; MRSA; Microbiome